Health ❯ Healthcare ❯ Chronic Diseases

Type 2 Diabetes

Management Strategies Treatment Options Cardiometabolic Health Management and Treatment Metabolic Disorders Cardiovascular Disease Weight Management Obesity Medication Effects Cardiovascular Risk

FDA Expands Mounjaro Label to Include Heart‑Attack and Stroke Prevention

The decision rests on a head‑to‑head trial showing about an 8% relative drop in major cardiovascular events versus dulaglutide.

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

FDA Clears Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Metformin Lowers Blood Sugar Through Brain Circuit, Mouse Study Finds

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Wave Life Sciences Shares Plunge 30% After Early Obesity Trial Readout

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

GLP-1 Drugs Tied to Lower Addiction Risk and Harms in Large VA Study

Abbott to Commercialize Novo Nordisk’s Semaglutide in India Under Extensior Brand

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Major Lancet Analysis Finds Most Statin Label Side Effects Not Caused by the Drugs

Oral Semaglutide Cuts Serious Heart-Failure Events 22% in Type 2 Diabetes With Heart Failure

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Real-World Study Finds Semaglutide and Tirzepatide Cut Cardiovascular Risk in Type 2 Diabetes

Metformin Blunts Exercise Benefits in Rutgers Randomized Trial

India Clears Ozempic for Type 2 Diabetes as Novo Nordisk Prepares Launch

EMA Approves Cardiovascular Indication for Novo Nordisk’s Rybelsus

17 Million U.S. Youth Eligible for GLP-1 Therapies Face Coverage and Care Barriers